# Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

> **NCT06855628** · PHASE2 · SUSPENDED · sponsor: **Stanford University** · enrollment: 10 (estimated)

## Conditions studied

- Glioma
- GBM

## Interventions

- **OTHER:** [6,6-²H₂]-Glucose

## Key facts

- **NCT ID:** NCT06855628
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-01-30
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** low accrual
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855628, "Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06855628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*